| PRECLINICAL | evidence | Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Activation of GLP-1R ameliorates alcohol withdrawal induced anxiety-like behavior by regulating neuronal mitochondrial quality control. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Turning back time: a comprehensive list of interventions that decrease next-generation epigenetic aging clocks in humans. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma. | Semaglutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Erratum. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study. | Semaglutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records. | Wegovy | — | 2026-01-01 |
| PRECLINICAL | evidence | Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide in Diabetic Periodontitis-Induced Osteoblast Ferroptosis: Pharmacological and Methodological Insights [Letter]. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol. | Semaglutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | A systematic review of semaglutide-associated kidney injury case reports. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation. | Ozempic | — | 2025-12-23 |
| PRECLINICAL | evidence | Assessing Predictive Performance of Fibrosis-4 Index in Settings With Lower Prevalence of Liver Fibrosis. | Wegovy | — | 2025-12-23 |
| PRECLINICAL | evidence | Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists. | Ozempic | — | 2025-12-12 |
| PRECLINICAL | evidence | Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders. | Ozempic | — | 2025-12-09 |
| PRECLINICAL | evidence | The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study. | Wegovy | — | 2025-12-09 |
| PRECLINICAL | evidence | Incretin receptor agonism during pregnancy: implications for mother and baby. | Ozempic | Glycemic control | 2025-12-08 |
| PRECLINICAL | evidence | A cardiovascular indication for oral semaglutide (Rybelsus). | Ozempic | — | 2025-12-08 |
| PRECLINICAL | evidence | Obesity: WHO calls for increased production of Ozempic and other weight loss drugs. | Ozempic | — | 2025-12-02 |
| PRECLINICAL | evidence | The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP-1 Agonists. | Ozempic | Glycemic control | 2025-12-01 |
| PRECLINICAL | evidence | Is Bariatric Surgery at Risk Due to Semaglutide? | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients. | Ozempic | Glycemic control | 2025-12-01 |
| PRECLINICAL | evidence | Unanticipated Residual Gastric Contents in an Appropriately Fasted Pediatric Patient on Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Case Report and Review of Perioperative Considerations. | Wegovy | — | 2025-12-01 |
| PRECLINICAL | evidence | First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | Facial aging after GLP-1 receptor agonist-induced weight loss: the emerging Ozempic face phenomenon. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes. | semaglutida | — | 2025-12-01 |
| PRECLINICAL | evidence | Yonder: Wishbones, gifts from patients, and Christmas Ozempic advertising. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape. | Ozempic | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists: trend, necessity, or blessing? | Wegovy | — | 2025-12-01 |
| PRECLINICAL | evidence | The unseen risk of Ozempic: NAION and vision damage. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | Even with diet and exercise, Ozempic use reduces perceived effort and praiseworthiness of resulting weight loss. | Ozempic | — | 2025-12-01 |
| PRECLINICAL | evidence | Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2). | Rybelsus | — | 2025-11-27 |
| PRECLINICAL | evidence | Accuracy of Large Language Model Responses Versus Internet Searches for Common Questions About Glucagon-Like Peptide-1 Receptor Agonist Therapy: Exploratory Simulation Study. | Ozempic | Weight & fat loss | 2025-11-24 |